Therapeutic inhibitor of vascular smooth muscle cells
US8067022B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 20, 2001 |
| Grant date | Nov 29, 2011 |
| Priority date | — |
| Expiry date | Jun 27, 2022 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/323
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.